Pharmacokinetics and bioequivalence of domestic and imported ramipril tablets
李雪宁,许剑安,陈伟力,徐红蓉,储楠楠,诸骏仁,黄锦培
DOI: https://doi.org/10.19577/j.cnki.issn10074406.2009.01.003
2009-01-01
Abstract:AIM To study the pharmacokinetics and bioequivalence of domestic and imported ramipril tablets in healthy subjects.METHODS Twenty-four healthy male subjects in a randomized crossover design were given a single oral dose of 10 mg ramipril.Plasma concentrations of the subjects were determined by LC-MS/MS.The pharmacokinetic parameters were calculated from 3P97 software.RESULTS The main pharmacokinetic parameters of domestic and imported formulations of ramipril were as follows: ramipril: ρmax were(28.26±12.54),(28.71±12.84)μg·L-1;tmax were(0.61±0.54),(0.51±0.10)h;AUC0→t were(24.52±13.21),(22.94±10.93)μg·h·L-1.The main metabolite-ramiprilat: ρmax were(24.37±13.65),(23.65±11.51)μg·L-1;tmax were(2.21±0.81),(1.96±0.67)h;AUC0→t were(127.21±63.04),(118.72±56.50)μg·h·L-1,respectively.The statistic analysis of the two formulations were calculated by analysis of variance,two one-sided t tests and confidence intervals.The results of ramipril and ramiprilat demonstrated that there were no significant differences between domestic and imported formulations(P>0.05).The mean relative bioavailability of domestic formulation of ramipril was(105.42±22.23) %,ramiprilat was(107.29±20.40) %(n=24).CONCLUSION The domestic and imported ramipril are bioequivalent.